Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Viviana Bazan, Marta Castiglia, Nadia Barraco, Antonio Russo, Sergio Castorina, Daniele Santini, Antonio Giordano, Daniele Santini, Lavinia Insalaco

Risultato della ricerca: Article

11 Citazioni (Scopus)

Abstract

Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticancer role, by inhibiting cell adhesion, invasion, cytoskeleton remodelling and proliferation in MCF-7 breast cancer cells. In order to identify the molecular mechanisms and signaling pathways underlying the anticancer activity exerted by ZOL, we analyzed for the first time the microRNA expression profile in breast cancer cells. A large-scale microarray analysis of 377 miRNAs was performed on MCF7 cells treated with 10 μM ZOL for 24 h compared to untreated cells. Furthermore, the expression of specific ZOL-induced miRNAs was analyzed in MCF-7 and SkBr3 cells through Real-time PCR. Low-dose treatment with ZOL significantly altered expression of 54 miRNAs. Nine upregulated and twelve downregulated miRNAs have been identified after 24 h of treatment. Also, ZOL induced expression of 11 specific miRNAs and silenced expression of 22 miRNAs. MiRNA data analysis revealed the involvement of differentially expressed miRNAs in PI3K/Akt, MAPK, Wnt, TGF-Β, Jak-STAT and mTOR signaling pathways, and regulation of actin cytoskeleton. Our results have been shown to be perfectly coherent with the recent findings reported in literature concerning changes in expression of some miRNAs involved in bone metastasis formation, progression, therapy resistance in breast cancer. In conclusion, this data supports the hypothesis that ZOL-induced modification of the miRNA expression profile contributes to the anticancer efficacy of this agent.
Lingua originaleEnglish
pagine (da-a)29321-29332
Numero di pagine12
RivistaOncotarget
Volume7
Stato di pubblicazionePublished - 2016

Fingerprint

zoledronic acid
MicroRNAs
Breast Neoplasms
MCF-7 Cells
Neoplasm Metastasis
Osteolysis

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? / Bazan, Viviana; Castiglia, Marta; Barraco, Nadia; Russo, Antonio; Castorina, Sergio; Santini, Daniele; Giordano, Antonio; Santini, Daniele; Insalaco, Lavinia.

In: Oncotarget, Vol. 7, 2016, pag. 29321-29332.

Risultato della ricerca: Article

Bazan, Viviana ; Castiglia, Marta ; Barraco, Nadia ; Russo, Antonio ; Castorina, Sergio ; Santini, Daniele ; Giordano, Antonio ; Santini, Daniele ; Insalaco, Lavinia. / Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. In: Oncotarget. 2016 ; Vol. 7. pagg. 29321-29332.
@article{8455ba4a075947819d474c9be265ad8d,
title = "Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?",
abstract = "Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticancer role, by inhibiting cell adhesion, invasion, cytoskeleton remodelling and proliferation in MCF-7 breast cancer cells. In order to identify the molecular mechanisms and signaling pathways underlying the anticancer activity exerted by ZOL, we analyzed for the first time the microRNA expression profile in breast cancer cells. A large-scale microarray analysis of 377 miRNAs was performed on MCF7 cells treated with 10 μM ZOL for 24 h compared to untreated cells. Furthermore, the expression of specific ZOL-induced miRNAs was analyzed in MCF-7 and SkBr3 cells through Real-time PCR. Low-dose treatment with ZOL significantly altered expression of 54 miRNAs. Nine upregulated and twelve downregulated miRNAs have been identified after 24 h of treatment. Also, ZOL induced expression of 11 specific miRNAs and silenced expression of 22 miRNAs. MiRNA data analysis revealed the involvement of differentially expressed miRNAs in PI3K/Akt, MAPK, Wnt, TGF-Β, Jak-STAT and mTOR signaling pathways, and regulation of actin cytoskeleton. Our results have been shown to be perfectly coherent with the recent findings reported in literature concerning changes in expression of some miRNAs involved in bone metastasis formation, progression, therapy resistance in breast cancer. In conclusion, this data supports the hypothesis that ZOL-induced modification of the miRNA expression profile contributes to the anticancer efficacy of this agent.",
author = "Viviana Bazan and Marta Castiglia and Nadia Barraco and Antonio Russo and Sergio Castorina and Daniele Santini and Antonio Giordano and Daniele Santini and Lavinia Insalaco",
year = "2016",
language = "English",
volume = "7",
pages = "29321--29332",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",

}

TY - JOUR

T1 - Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

AU - Bazan, Viviana

AU - Castiglia, Marta

AU - Barraco, Nadia

AU - Russo, Antonio

AU - Castorina, Sergio

AU - Santini, Daniele

AU - Giordano, Antonio

AU - Santini, Daniele

AU - Insalaco, Lavinia

PY - 2016

Y1 - 2016

N2 - Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticancer role, by inhibiting cell adhesion, invasion, cytoskeleton remodelling and proliferation in MCF-7 breast cancer cells. In order to identify the molecular mechanisms and signaling pathways underlying the anticancer activity exerted by ZOL, we analyzed for the first time the microRNA expression profile in breast cancer cells. A large-scale microarray analysis of 377 miRNAs was performed on MCF7 cells treated with 10 μM ZOL for 24 h compared to untreated cells. Furthermore, the expression of specific ZOL-induced miRNAs was analyzed in MCF-7 and SkBr3 cells through Real-time PCR. Low-dose treatment with ZOL significantly altered expression of 54 miRNAs. Nine upregulated and twelve downregulated miRNAs have been identified after 24 h of treatment. Also, ZOL induced expression of 11 specific miRNAs and silenced expression of 22 miRNAs. MiRNA data analysis revealed the involvement of differentially expressed miRNAs in PI3K/Akt, MAPK, Wnt, TGF-Β, Jak-STAT and mTOR signaling pathways, and regulation of actin cytoskeleton. Our results have been shown to be perfectly coherent with the recent findings reported in literature concerning changes in expression of some miRNAs involved in bone metastasis formation, progression, therapy resistance in breast cancer. In conclusion, this data supports the hypothesis that ZOL-induced modification of the miRNA expression profile contributes to the anticancer efficacy of this agent.

AB - Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticancer role, by inhibiting cell adhesion, invasion, cytoskeleton remodelling and proliferation in MCF-7 breast cancer cells. In order to identify the molecular mechanisms and signaling pathways underlying the anticancer activity exerted by ZOL, we analyzed for the first time the microRNA expression profile in breast cancer cells. A large-scale microarray analysis of 377 miRNAs was performed on MCF7 cells treated with 10 μM ZOL for 24 h compared to untreated cells. Furthermore, the expression of specific ZOL-induced miRNAs was analyzed in MCF-7 and SkBr3 cells through Real-time PCR. Low-dose treatment with ZOL significantly altered expression of 54 miRNAs. Nine upregulated and twelve downregulated miRNAs have been identified after 24 h of treatment. Also, ZOL induced expression of 11 specific miRNAs and silenced expression of 22 miRNAs. MiRNA data analysis revealed the involvement of differentially expressed miRNAs in PI3K/Akt, MAPK, Wnt, TGF-Β, Jak-STAT and mTOR signaling pathways, and regulation of actin cytoskeleton. Our results have been shown to be perfectly coherent with the recent findings reported in literature concerning changes in expression of some miRNAs involved in bone metastasis formation, progression, therapy resistance in breast cancer. In conclusion, this data supports the hypothesis that ZOL-induced modification of the miRNA expression profile contributes to the anticancer efficacy of this agent.

UR - http://hdl.handle.net/10447/212482

UR - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path[]=8722&path[]=26236

M3 - Article

VL - 7

SP - 29321

EP - 29332

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

ER -